Shots:
Abogen has entered into a licensing & option agreement, granting Novartis an exclusive worldwide license to ABO2203, as well as options to exclusively license other potential programs that leverage Abogen's RNA platform
As per the deal, Abogen will receive ~$575M upfront &, if all options on all programs are exercised, Abogen will gain ~$7.2B…
